Navigation Links
CV Therapeutics Reports 2008 Second Quarter Financial Results
Date:7/31/2008

.8 million for the quarter ended June 30, 2008. This compares to total costs and expenses of $53.1 million for the prior quarter ended March 31, 2008 and $83.1 million for the same quarter in 2007. The increase of total costs and expenses in the quarter ended June 30, 2008 compared to the prior quarter ended March 31, 2008 was primarily due to higher Ranexa marketing and sales expense.

The decrease in costs and expenses in the quarter ended June 30, 2008 compared to the same period in 2007 was due in part to $18.6 million of non-recurring charges relating to the Company's restructuring plan initiated in May 2007 to lower annual operating expenses. The balance of the year-over-year decline was primarily due to lower research and development expenses, reduction in personnel-related expenses related to cost savings from the May 2007 restructuring plan and lower marketing and sales expenses. These decreases were partially offset by higher cost of sales due to higher sales of Ranexa.

During the quarter ended June 30, 2008 the Company had several unusual events which affected our quarterly cash flow. We received a $12.0 million milestone from Astellas upon FDA approval of Lexiscan(TM). We also received two payments totaling $185.0 million from TPG-Axon Capital in exchange for rights to 50 percent of our royalty on North American sales of Lexiscan(TM). Offsetting these cash inflows, $48.4 million was used to repurchase $53.0 million face value of our convertible subordinated notes. Additionally, the Company made an estimated tax payment of $3.2 million for alternative minimum tax primarily as a result of the cash received from TPG-Axon Capital.

At June 30, 2008, the Company had cash, cash equivalents, marketable securities and restricted cash of $274.7 million compared to $151.0 million at March 31, 2008. Excluding the unusual cash items above, our cash utilized for the quarter ended June 30, 2008 was $21.7 million. This compares to our cash utilized f
'/>"/>

SOURCE CV Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... 10, 2014 OMICS Group’s 5th International ... 18-20 August, 2014 at Double Tree by Hilton Beijing, ... developments in Analytical & Bioanalytical research methods only to ... on this occasion, Dr. Srinubabu Gedela, MD of OMICS ... is a remarkable one in bringing a unique and ...
(Date:7/10/2014)... Senior supply chain management executives from over ... challenges of “Reducing Cost, Lead Time, & Defects in ... Describing the partnership of the Bio Supply Management Alliance ... ( SCMI) of the University of San Diego ... Kroc Institute of Peace and Justice in San Diego, ...
(Date:7/10/2014)... On July 9 Prime Minister ... Russia,s first national "Industry" award ... is developing a unique project called MabNext . ... number of innovative drugs based on monoclonal antibodies for ... place at the International Exhibition "Innoprom 2014" in Ekaterinburg. ...
(Date:7/10/2014)... , July 10, 2014 /PRNewswire-iReach/ -- ... and interpretation, today announced an agreement with ... analytics for Lineagen,s NextStep Dx PLUS.  ... neurodevelopmental and neurological disorders, currently offers FirstStep ... (CMA) testing service used by healthcare providers ...
Breaking Biology Technology:A Critical Review of Analytical Techniques for Improved Living Standards 2A Critical Review of Analytical Techniques for Improved Living Standards 3A Critical Review of Analytical Techniques for Improved Living Standards 4Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 2Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 3Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 4Dmitry Medvedev Presented BIOCAD the First National "Industry" Award 2Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 2Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 3Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 4
... 15 3SBio Inc. (Nasdaq:,SSRX), a leading China-based ... biopharmaceutical products, today,announced the results of the shareholder ... held on September 12, 2008 (Friday) at 10:00 ... shareholders re-elected Dr. Jing Lou,Liping Xu, Bin Huang, ...
... Plans to Phase in Routine Vaccination Program ... and Young Children -, COLLEGEVILLE, Pa., Sept. ... WYE ), today announced that,South Africa has ... (Pneumococcal Saccharide Conjugated Vaccine,Adsorbed), a vaccine which helps ...
... Biopharma,Inc. (OTC Bulletin Board: CBPC) announced today that it ... of Delaware an amendment to its Certificate,of Incorporation to ... common stock ("Common Stock") will begin trading on a,reverse-split ... CHBO., By unanimous written consent dated July 3, ...
Cached Biology Technology:South Africa Begins Introduction of PREVENAR into Childhood Immunization Program 2South Africa Begins Introduction of PREVENAR into Childhood Immunization Program 3South Africa Begins Introduction of PREVENAR into Childhood Immunization Program 4China Biopharma Effects 1 for 100 Reverse Stock Split 2China Biopharma Effects 1 for 100 Reverse Stock Split 3
(Date:7/11/2014)... City of Entiat on Tuesday, July 8, 2014. Despite ... to over 1,000 acres by evening. Three outbuildings were ... by the Washington Department of Natural Resources. The ... developing fire control strategies and tactics. Other cooperators include ... Natural Resources, (WA DNR), Bureau of Land Management, Chelan ...
(Date:7/11/2014)... of Standards and Technology (NIST) need a special ... often prove that necessity is truly the mother ... M. Lorna De Leoz and Stephen Stein, NIST ... Glycomics is the study of the abundant, often-branched ... proteins and lipids and influence cellular processes, including ...
(Date:7/11/2014)... University, Sweden, have explored two different ways that ... leading to the formation of oxygen molecules in ... the scientific journal Nature Communications . , ... synthetic catalysts for water oxidation, which are key ... direct storage of solar energy in fuels like ...
Breaking Biology News(10 mins):Molecular snapshots of oxygen formation in photosynthesis 2
... exposed to low doses of atrazine, a widely used herbicide, ... through puberty later than non-exposed animals. The research adds to ... used to control weeds and grasses in crops such as ... to be relatively persistent in the environment, potentially finding their ...
... current issue of Deutsches rzteblatt International (Dtsch ... pharmacologist, and coauthors present the PRISCUS List: a list ... effects when given to elderly patients. The authors ... Germany in the setting of a joint project entitled ...
... Chinese on EurekAlert! Chinese . ... Medicine, Hershey, Pennsylvania have discovered that the Opioid Growth ... important system with potent antitumor properties, has controlled entry ... passage of OGF-OGFr is critical to cell proliferation and ...
Cached Biology News:Atrazine causes prostate inflammation in male rats and delays puberty 2Regulation of cell proliferation is dependent on nucleocytoplasmic trafficking 2Regulation of cell proliferation is dependent on nucleocytoplasmic trafficking 3